32 results about "Mass cytometry" patented technology

This specification discloses systems, methods, devices, and other techniques for a tissue based classifier. Systems and methods of predicting causes of allograft inflammation are disclosed. In another aspect, a system comprising an imaging mass cytometry device configured to scan a tissue sample to collect imaging mass cytometry data and a computing system operating an allograft inflammation classifier configured to identify a type of allograft inflammation in the tissue sample by comparing a biosignature with imaging mass cytometry data is disclosed.

Described herein are nanoparticles comprising NaLnF4, wherein Ln includes all non-radioactive lanthanide elements, or NaYF4, and methods of making and using the same. The nanoparticles may optionally be modified with PEG or zwitterionic polymers containing a bisphosphonate end group, wherein the bisphosphonate end group optionally comprises an aminohexyl group. As described herein. NaLnF4 or NaYF4 nanoparticles may be used as high-sensitivity reagents for mass cytometry.

We describe in this application the analysis of samples using elemental or mass spectrometry and the analysis of samples, such as biological samples by suspension mass cytometry or imaging mass cytometry and an inductively coupled plasma torch with reverse vortex flow for elemental analysis and a method of operating an ICP torch configured to interface with a spectrometer.

Disclosed is a method of differentiating empty capsids from full capsids or loaded and unloaded non-viral gene therapy vectors in a viral preparation. The method comprises the steps of: a) providing a preparation of viral particles or gene therapy vectors; b) subjecting the preparation to interferometric scattering mass cytometry (ISCAMS) in an interferometric scattering microscope to generate mass distribution data of the viral particles; c) determining from the mass distribution data the level of empty capsids and capsids containing genomes or the level of loaded and unloaded vectors in the viral particles.

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to mass tags and additional reagents to reduce background and / or maintain target binding of mass tagged specific binding partners (SBPs), and schemes for associating a plurality of mass tags with a single SBP. As such, embodiments include any combination of one or more reagents and their use. The reagents, kits and methods herein may be used for mass cytometry, including imaging mass cytometry. In some aspects, reagents, kits or methods may be used for delivery of a large number of radioisotopes to a target analyte, for example for therapeutic use or radiometric detection. In certain aspects, only non-radioactive isotopes may be used for mass cytometry.

1. Name of the design product: Mass spectrometry flow cytometry sampler. 2. Use of the design product: For mass spectrometry flow cytometry sampling. 3. Design key points of the design product: Lies in the shape. 4. Picture or photograph that best shows the design key points: Perspective view 1.

The present invention relates to the high resolution imaging of samples using imaging mass spectrometry (IMS) and to the imaging of biological samples by imaging mass cytometry (IMC™) in which labelling atoms are detected by IMS. LA-ICP-MS (a form of IMS in which the sample is ablated by a laser, the ablated material is then ionised in an inductively coupled plasma before the ions are detected by mass spectrometry) has been used for analysis of various substances, such as mineral analysis of geological samples, analysis of archaeological samples, and imaging of biological substances. However, traditional LA-ICP-MS systems and methods may not provide high resolution. Described herein are methods and systems for high resolution IMS and IMC.

Embodiments of the present invention relate to reagents and their use for elemental imaging mass spectrometry of biological samples. Embodiments include a method for quantifying one or more analytes within a sample. The method may include providing the sample. One or more analytes may be immobilised to a mass cytometry sample carrier. The sample may have been labelled with one or more mass-tagged SBPs including one or more labelling atoms. The method may include performing mass cytometry on the sample to determine a level of the one or more labelling atoms, where the level of the one or more labelling atoms corresponds to the copy number of the one or more analytes to quantify the analytes.

Aspects of the present disclosure include methods for processing cytometer data, such as group-wise analysis of cytometer data (e.g., flow cytometry data in FCS format, mass cytometry data, genomic cytometry data). Methods according to certain embodiments include generating a composite population of events including data accessors from the cytometry data, for example, the composite population of cytometer data is from two or more different samples that are kept as separate raw data files (e.g., not concatenated to form a single combined data file). Systems are also described that have an input module for receiving cytometer data and a processor with a memory having instructions for performing the subject methods. Non-transitory computer readable storage media are also provided.

Embodiments of the present invention relate to reagents and their use for elemental imaging mass spectrometry of biological samples. Embodiments include a method for quantifying one or more analytes within a sample. The method may include providing the sample. One or more analytes may be immobilised to a mass cytometry sample carrier. The sample may have been labelled with one or more mass-tagged SB Ps including one or more labelling atoms. The method may include performing mass cytometry on the sample to determine a level of the one or more labelling atoms, where the level of the one or more labelling atoms corresponds to the copy number of the one or more analytes to quantify the analytes.

Inductively coupled plasma (ICP) analyzers use an ICP torch to generate plasma in which the sample is atomized and ionized. Analysis of the atomic ions can be performed using atomic analysis, such as mass spectrometry (MS) or atomic emission spectrometry (AES). Particle-based ICP analysis involves analyzing particles (e.g., cells, magnetic beads, or laser ablation plumes) by atomizing and ionizing them in an ICP torch chamber followed by atomic analysis. In mass cytometry, the mass tags of the particles are analyzed using mass spectrometry, such as ICP-MS. The systems and methods of this application include one or more of the following: a removable ICP torch holder assembly, an external ignition device, an ICP induction coil including annular fins, a particle-suspended sample introduction jet, and its ICP analyzer.

Provided are novel metal tags, metal-tagged probes and methods of making and using them for barcoding and mass cytometry. Also provided are kits comprising metal-tagged probes.

We describe in this application the analysis of samples using elemental or mass spectrometry and the analysis of samples, such as biological samples by suspension mass cytometry or imaging mass cytometry and an inductively coupled plasma torch with reverse vortex flow for elemental analysis and a method of operating an ICP torch configured to interface with a spectrometer.

This invention provides a mass tag for mass flow cytometry, its preparation method, and its application. The mass tag provided by this invention has the chemical structure shown in Formula 1. The compound shown in Formula 1 provided by this invention offers a new channel for CyTOF single-cell analysis, suitable for the detection of various biomarkers such as live cells and proteins. It is of great significance for more in-depth and comprehensive analysis of changes in various cell subtypes and their proportions, and for predicting the changing trends of clinical disease courses, showing good clinical application prospects and significant social benefits.

The present invention relates to the high resolution imaging of samples using imaging mass spectrometry (IMS) and to the imaging of biological samples by imaging mass cytometry (IMC™) in which labelling atoms are detected by IMS. LA-ICP-MS (a form of IMS in which the sample is ablated by a laser, the ablated material is then ionised in an inductively coupled plasma before the ions are detected by mass spectrometry) has been used for analysis of various substances, such as mineral analysis of geological samples, analysis of archaeological samples, and imaging of biological substances. However, traditional LA-ICP-MS systems and methods may not provide high resolution. Described herein are methods and systems for high resolution IMS and IMC.

The embodiment of the invention discloses a disinfection cleaning solution for a mass spectrometry flow cytometer and a preparation method of the disinfection cleaning solution. The disinfection cleaning solution is prepared from the following raw materials in percentage by weight: 0.1%-0.5% of trypsin, 0.1%-0.5% of IV type collagenase, 0.1%-0.5% of I type collagenase, 0.1%-1% of DNA enzyme, 0.1%-0.5% of protease, 0.01%-0.05% of EDTA (Ethylene Diamine Tetraacetic Acid), 0.1%-2% of a surfactant disinfectant and the balance of deionized water. When the disinfection cleaning solution is used for cleaning a key component glass atomizer of a mass spectrometry flow cytometry, residual components, including collagen, extracellular matrix, histone, DNA and the like, possibly existing in the using process can be effectively digested and enzymolyzed, and the disinfection cleaning solution has an excellent cleaning effect.

The invention provides a reagent composition for detecting whole-blood-method myeloid-derived suppressor cells through mass spectrum flow cytometry and application of the reagent composition. The reagent composition comprises three groups of reagents and is a flow cytometry detection composition capable of being used for detecting whole-blood-method myeloid-derived suppressor cells through mass spectrometry flow cytometry, when the reagent composition is applied, 21 reagents are used in a single tube at the same time, and the three groups of reagents are added in sequence and used for a sample in the same tube. The reagent provided by the invention can be applied to mass spectrometry flow cytometry to detect whole-blood-method myeloid-derived suppressor cells and evaluate whether a detected sample has a myeloid suppression state or not.

Aspects of the subject application include applying a spatial barcode to a cellular sample and then performing suspension mass cytometry on the cellular sample. For example, a sample barcode comprising a known distribution of sample barcode isotopes may be applied to the sample such that cells in different locations receive a unique combination or ratio of barcode isotopes, after which cells are suspended (e.g., dissociated from tissue) and processed by suspension mass cytometry. While barcode isotopes are described in a number of embodiments herein, non-enriched elements may be used instead of, or in addition to, enriched isotopes. Mass cytometry methods and reagents are discussed below, followed by a further description of spatial barcoding and kits thereof.

A method for constructing a diagnostic model for distinguishing between benign and malignant pulmonary nodules on the basis of a single-cell immune profile, which method comprises: obtaining PBMCs from a peripheral blood sample, and performing mass cytometry analysis on the PBMCs to obtain a mass cytometry analysis dataset; classifying cells into different phenotypes on the basis of marker expression and by using a PARC clustering algorithm; and using the expression proportion of each cell subgroup as modeling features to obtain a diagnostic model for distinguishing between benign and malignant pulmonary nodules, thereby realizing the screening and early diagnosis of lung cancer. The model features non-invasiveness, high sensitivity and high specificity, improves the diagnostic accuracy of lung cancer screening, and provides patients with earlier treatment opportunities and more suitable surgical approaches.

The present invention provides a method for detecting antibodies by mass cytometry and its application, which relates to the technical field of antibody detection. In the present invention, the amino group at the Fc end of the antibody is modified to form a structure that can be reduced to a thiol group, and then reduced to a thiol group, which binds to the maleimide on the FluoReporter product X8-polymer, greatly increasing the number of polymers linked to one antibody, meaning that more metals are linked, and greatly enhancing the detected metal signal. The present invention solves the technical problems that when using the labeling reagent X8-polymer in mass cytometry to detect weakly expressed antigen proteins, the signal is not obvious, and when detecting a large number of markers, using low-sensitivity metal tags results in low metal channel signals.

The present disclosure relates to metal labelled polymer microbeads and in particular to lanthanide labelled polymer microbeads for mass cytometry bead based assays and multiplexing applications. The polymer microbead comprises a copolymer comprising a structural monomer and a metal-chelating monomer.

Methods that include tagging at least one cell with a MXene, the cell optionally being an immune cell; and detecting at least one component of the MXene using one or more of single-cell mass cytometry by time-of-flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging (MIBI-TOF). Systems that include a cell tagged with an amount of a MXene; and a detection train configured for at least one of time of flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging by time-of-flight (MIBI-TOF) that detects the MXene. Methods that include tagging a population of cells with at least one MXene: and processing the population of cells with at least one of time-of-flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging by time-of-flight (MIBI-TOF) that detects the at least MXene; and relating the detection of the at least one MXene to a characteristic of the population of cells.

Embodiments of the present invention relate to replacement of the previous ICP-based ionisation system with a new laser ionisation system, providing improved mass spectrometer-based apparatus and methods for using them to analyse samples, in particular the use of mass spectrometry mass cytometry, imaging mass spectrometry and imaging mass cytometry, for the analysis of biological samples. Accordingly, embodiments of the present invention provide an apparatus, for example a mass cytometer, comprising: 1) a sampler; 2) a laser ionisation system to receive material removed from the sample by the sampler, wherein the laser ionisation system comprises an ionisation system conduit and a pulsed laser adapted to ionise sample material passing through or exiting the ionisation system conduit; and 3) a mass spectrometer to receive elemental ions from said ionisation system and to analyse said elemental ions.

We describe in this application the analysis of samples using elemental or mass spectrometry and the analysis of samples, such as biological samples by suspension mass cytometry or imaging mass cytometry and an inductively coupled plasma torch with reverse vortex flow for elemental analysis and a method of operating an ICP torch configured to interface with a spectrometer.

The present disclosure relates to systems and methods for high-speed modulated sample imaging. Disclosed herein are systems and methods for performing imaging mass cytometry, including labeling atoms by elemental (e.g., atomic) mass spectrometry. Various aspects include sampling systems with femtosecond (fs) lasers and / or laser scanning and methods using femtosecond (fs) lasers and / or laser scanning. Alternatively or additionally, various aspects include systems and methods for co-registering other imaging modalities with imaging mass cytometry.

To provide systems and method for imaging mass spectrometry, including imaging mass cytometry.SOLUTION: Apparatus and method for imaging mass spectrometry (IMS) that improve speed of sample acquisition, signal sensitivity, and / or signal stability may minimize the transfer time of and / or the spread of plume of a sample material removed from a sample to be transferred to components of the imaging mass spectrometer or mass cytometer that ionize and analyze the sample material.SELECTED DRAWING: Figure 1

1. Name of the Design Product: Mass Cytometry Analyzer. 2. Use of the Design Product: This product is used for multi-parameter detection of single cells. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective View 1.

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to the mass tags, and additional reagents to reduce background and / or preserve specific binding partner (SBP) binding of the mass label, as well as protocols for associating multiple mass tags with a single SBP. Thus, embodiments include any combination of one or more reagents and uses thereof. The reagents, kits, and methods herein are useful in mass cytometry, including imaging mass cytometry. In some aspects, the reagents, kits, or methods are useful for delivering a large number of radioisotopes to a target analyte, e.g., for therapeutic use or radioimaging. In certain aspects, only non-radioactive isotopes are used in mass cytometry.

The invention discloses a polymer metal chelating tag for mass spectrometry flow cytometry as well as a preparation method and application of the polymer metal chelating tag. The structural general formula of the polymer metal chelating label is nDOTA-PEG-Linker, and the structural general formula of the polymer metal chelating label is nDOTA-PEG-Linker. Wherein DOTA represents a polypeptide chain segment containing DOTA, n represents the number of DOTA chelating units accurately introduced through solid-phase polypeptide synthesis, and n is an integer ranging from 4 to 16; pEG is polyethylene glycol as a spacer group, the mobility of a peptide chain can be improved by a flexible chain, the accessibility of Linker is improved, and the reaction efficiency is improved; linker refers to a group capable of being directionally coupled with an antibody. The reagent label prepared by adopting an automatic solid-phase synthesizer is accurate and small in molecular weight, simple and convenient in synthesis steps, capable of chelating various metal elements including lanthanide metals and other heavy metals, and capable of efficiently labeling an antibody due to small steric hindrance, and the labeled antibody has high specificity and high sensitivity and can be used for mass spectrum flow type detection.

The invention relates to the technical field of medical biology, in particular to a living tumor heterogeneity analysis method combining elastic ultrasound and a mass spectrum flow technology, which comprises the following steps: firstly, carrying out heterogeneity detection on living tumor tissues based on an elastic ultrasound imaging technology to obtain an elastic ultrasound imaging result; and then, based on an elastic ultrasonic imaging result, screening tumor specimens in different development stages, and analyzing immune cell composition and heterogeneity characteristics of the tumor specimens by adopting a mass spectrum flow type technology. According to the living tumor heterogeneity analysis method combining the elastic ultrasound and the mass spectrum flow technology, positioning and qualitative detection are carried out on tumor primary lesions through the elastic ultrasound imaging technology, and multi-primary-lesion tumor cell immune microenvironment characteristics are analyzed in combination with the mass spectrum flow technology.